GBM immunotherapy: Exploring molecular and clinical frontiers
GBM is the most common, aggressive, and intracranial primary brain tumor; it originates from
the glial progenitor cells, has poor overall survival (OS), and has limited treatment options. In …
the glial progenitor cells, has poor overall survival (OS), and has limited treatment options. In …
Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases
Y Zhang, M Sun, H Zhao, Z Wang, Y Shi… - International Journal …, 2023 - Taylor & Francis
Dichloroacetate (DCA) is an investigational drug used to treat lactic acidosis and malignant
tumours. It works by inhibiting pyruvate dehydrogenase kinase and increasing the rate of …
tumours. It works by inhibiting pyruvate dehydrogenase kinase and increasing the rate of …
[HTML][HTML] Blocking cerebral lymphatic system reduces central and peripheral inflammatory response in ischemic stroke
L Yang, Q Li, K Wang, H Liu, X Yang, Y Xu, Y Chen… - Brain Research, 2024 - Elsevier
Reduced blood supply to the brain activates the intracranial inflammatory response, a key
contributor to secondary brain damage in ischemic stroke. Post-stroke, activation of …
contributor to secondary brain damage in ischemic stroke. Post-stroke, activation of …